These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2871 related articles for article (PubMed ID: 26924089)

  • 21. Loss of ATOH8 Increases Stem Cell Features of Hepatocellular Carcinoma Cells.
    Song Y; Pan G; Chen L; Ma S; Zeng T; Man Chan TH; Li L; Lian Q; Chow R; Cai X; Li Y; Li Y; Liu M; Li Y; Zhu Y; Wong N; Yuan YF; Pei D; Guan XY
    Gastroenterology; 2015 Oct; 149(4):1068-81.e5. PubMed ID: 26099525
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells.
    Wan S; Zhao E; Kryczek I; Vatan L; Sadovskaya A; Ludema G; Simeone DM; Zou W; Welling TH
    Gastroenterology; 2014 Dec; 147(6):1393-404. PubMed ID: 25181692
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.
    Dong J; Zhai B; Sun W; Hu F; Cheng H; Xu J
    PLoS One; 2017; 12(9):e0185088. PubMed ID: 28934275
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sorafenib enhances the chemotherapeutic efficacy of S-1 against hepatocellular carcinoma through downregulation of transcription factor E2F-1.
    Zhai JM; Yin XY; Lai YR; Hou X; Cai JP; Hao XY; Liang LJ; Zhang LJ
    Cancer Chemother Pharmacol; 2013 May; 71(5):1255-64. PubMed ID: 23435877
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Strong enhancement by IGF1-R antagonists of hepatocellular carcinoma cell migration inhibition by Sorafenib and/or vitamin K1.
    D'Alessandro R; Refolo MG; Lippolis C; Carella N; Messa C; Cavallini A; Carr BI
    Cell Oncol (Dordr); 2018 Jun; 41(3):283-296. PubMed ID: 29470830
    [TBL] [Abstract][Full Text] [Related]  

  • 26. mTORC1 Up-Regulates GP73 to Promote Proliferation and Migration of Hepatocellular Carcinoma Cells and Growth of Xenograft Tumors in Mice.
    Chen X; Wang Y; Tao J; Shi Y; Gai X; Huang F; Ma Q; Zhou Z; Chen H; Zhang H; Liu Z; Sun Q; Peng H; Chen R; Jing Y; Yang H; Mao Y; Zhang H
    Gastroenterology; 2015 Sep; 149(3):741-52.e14. PubMed ID: 25980751
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
    Liang Y; Zheng T; Song R; Wang J; Yin D; Wang L; Liu H; Tian L; Fang X; Meng X; Jiang H; Liu J; Liu L
    Hepatology; 2013 May; 57(5):1847-57. PubMed ID: 23299930
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models.
    You A; Cao M; Guo Z; Zuo B; Gao J; Zhou H; Li H; Cui Y; Fang F; Zhang W; Song T; Li Q; Zhu X; Yin H; Sun H; Zhang T
    J Hematol Oncol; 2016 Mar; 9():20. PubMed ID: 26957312
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A polymeric nanoparticle formulation of curcumin in combination with sorafenib synergistically inhibits tumor growth and metastasis in an orthotopic model of human hepatocellular carcinoma.
    Hu B; Sun D; Sun C; Sun YF; Sun HX; Zhu QF; Yang XR; Gao YB; Tang WG; Fan J; Maitra A; Anders RA; Xu Y
    Biochem Biophys Res Commun; 2015 Dec; 468(4):525-32. PubMed ID: 26482853
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Down-Regulation of TGF-β Expression Sensitizes the Resistance of Hepatocellular Carcinoma Cells to Sorafenib.
    Kang D; Han Z; Oh GH; Joo Y; Choi HJ; Song JJ
    Yonsei Med J; 2017 Sep; 58(5):899-909. PubMed ID: 28792132
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TLR3 agonist and Sorafenib combinatorial therapy promotes immune activation and controls hepatocellular carcinoma progression.
    Ho V; Lim TS; Lee J; Steinberg J; Szmyd R; Tham M; Yaligar J; Kaldis P; Abastado JP; Chew V
    Oncotarget; 2015 Sep; 6(29):27252-66. PubMed ID: 26287667
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sorafenib inhibits macrophage-induced growth of hepatoma cells by interference with insulin-like growth factor-1 secretion.
    Sprinzl MF; Puschnik A; Schlitter AM; Schad A; Ackermann K; Esposito I; Lang H; Galle PR; Weinmann A; Heikenwälder M; Protzer U
    J Hepatol; 2015 Apr; 62(4):863-70. PubMed ID: 25463538
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling.
    Hsu FT; Liu YC; Chiang IT; Liu RS; Wang HE; Lin WJ; Hwang JJ
    Int J Oncol; 2014 Jul; 45(1):177-88. PubMed ID: 24807012
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neutrophils recruit regulatory T-cells into tumors via secretion of CCL17--a new mechanism of impaired antitumor immunity.
    Mishalian I; Bayuh R; Eruslanov E; Michaeli J; Levy L; Zolotarov L; Singhal S; Albelda SM; Granot Z; Fridlender ZG
    Int J Cancer; 2014 Sep; 135(5):1178-86. PubMed ID: 24501019
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma.
    Tovar V; Cornella H; Moeini A; Vidal S; Hoshida Y; Sia D; Peix J; Cabellos L; Alsinet C; Torrecilla S; Martinez-Quetglas I; Lozano JJ; Desbois-Mouthon C; Solé M; Domingo-Domenech J; Villanueva A; Llovet JM
    Gut; 2017 Mar; 66(3):530-540. PubMed ID: 26658144
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potential synergistic anti-tumor activity between lenalidomide and sorafenib in hepatocellular carcinoma.
    Ou DL; Chang CJ; Jeng YM; Lin YJ; Lin ZZ; Gandhi AK; Liao SC; Huang ZM; Hsu C; Cheng AL
    J Gastroenterol Hepatol; 2014 Dec; 29(12):2021-31. PubMed ID: 25160036
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stearoyl-CoA desaturase regulates sorafenib resistance via modulation of ER stress-induced differentiation.
    Ma MKF; Lau EYT; Leung DHW; Lo J; Ho NPY; Cheng LKW; Ma S; Lin CH; Copland JA; Ding J; Lo RCL; Ng IOL; Lee TKW
    J Hepatol; 2017 Nov; 67(5):979-990. PubMed ID: 28647567
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Suppression of natural killer cells by sorafenib contributes to prometastatic effects in hepatocellular carcinoma.
    Zhang QB; Sun HC; Zhang KZ; Jia QA; Bu Y; Wang M; Chai ZT; Zhang QB; Wang WQ; Kong LQ; Zhu XD; Lu L; Wu WZ; Wang L; Tang ZY
    PLoS One; 2013; 8(2):e55945. PubMed ID: 23409093
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In Hepatocellular Carcinoma miR-221 Modulates Sorafenib Resistance through Inhibition of Caspase-3-Mediated Apoptosis.
    Fornari F; Pollutri D; Patrizi C; La Bella T; Marinelli S; Casadei Gardini A; Marisi G; Baron Toaldo M; Baglioni M; Salvatore V; Callegari E; Baldassarre M; Galassi M; Giovannini C; Cescon M; Ravaioli M; Negrini M; Bolondi L; Gramantieri L
    Clin Cancer Res; 2017 Jul; 23(14):3953-3965. PubMed ID: 28096271
    [No Abstract]   [Full Text] [Related]  

  • 40. Downregulation of triggering receptor expressed on myeloid cells 1 inhibits invasion and migration of liver cancer cells by mediating macrophage polarization.
    Chen M; Lai R; Lin X; Chen W; Wu H; Zheng Q
    Oncol Rep; 2021 Apr; 45(4):. PubMed ID: 33649843
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 144.